NASDAQ:VRCA - Nasdaq - US92511W1080 - Common Stock - Currency: USD
0.469
0 (-0.28%)
The current stock price of VRCA is 0.469 USD. In the past month the price increased by 11.67%. In the past year, price decreased by -93.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
JNJ | JOHNSON & JOHNSON | 15.53 | 375.64B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
PFE | PFIZER INC | 7.54 | 137.25B | ||
SNY | SANOFI-ADR | 14.36 | 135.72B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
ZTS | ZOETIS INC | 26.59 | 70.23B | ||
HLN | HALEON PLC-ADR | 21.84 | 48.25B |
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
VERRICA PHARMACEUTICALS INC
10 N High St Ste 200
West Chester PENNSYLVANIA 19380 US
CEO: Ted White
Employees: 71
Phone: 14844533300
The current stock price of VRCA is 0.469 USD. The price decreased by -0.28% in the last trading session.
The exchange symbol of VERRICA PHARMACEUTICALS INC is VRCA and it is listed on the Nasdaq exchange.
VRCA stock is listed on the Nasdaq exchange.
12 analysts have analysed VRCA and the average price target is 3.4 USD. This implies a price increase of 624.94% is expected in the next year compared to the current price of 0.469. Check the VERRICA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VERRICA PHARMACEUTICALS INC (VRCA) has a market capitalization of 43.36M USD. This makes VRCA a Nano Cap stock.
VERRICA PHARMACEUTICALS INC (VRCA) currently has 71 employees.
VERRICA PHARMACEUTICALS INC (VRCA) has a resistance level at 0.48. Check the full technical report for a detailed analysis of VRCA support and resistance levels.
The Revenue of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 104.5% in the next year. Check the estimates tab for more information on the VRCA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VRCA does not pay a dividend.
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2025-05-07.
VERRICA PHARMACEUTICALS INC (VRCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
The outstanding short interest for VERRICA PHARMACEUTICALS INC (VRCA) is 5.83% of its float. Check the ownership tab for more information on the VRCA short interest.
ChartMill assigns a technical rating of 1 / 10 to VRCA. When comparing the yearly performance of all stocks, VRCA is a bad performer in the overall market: 96.53% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VRCA. VRCA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -5.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -141.46% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 77% to VRCA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 79.96% and a revenue growth 104.5% for VRCA